AIMC Topic: Thiohydantoins

Clear Filters Showing 1 to 2 of 2 articles

A machine learning model (Sol_ME) assisted development of a unit-dose lipid formulation for apalutamide: formulation, pharmacokinetics, and pharmacodynamics evaluation.

International journal of pharmaceutics Aug 24, 2025
PURPOSE: The development of a novel lipid-based formulation for apalutamide, a potent androgen receptor inhibitor for non-metastatic castration-resistant prostate cancer (nmCRPC), is explored in this study.
Humans Machine Learning Animals Male Cell Line, Tumor Lipids Solubility Biological Availability Drug Compounding Capsules Prostatic Neoplasms, Castration-Resistant Chemistry, Pharmaceutical Excipients Androgen Receptor Antagonists Thiohydantoins
View on PubMed DOI

Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer.

JCO precision oncology Jan 31, 2025
PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histo...
Humans Artificial Intelligence Aged Male Middle Aged Treatment Outcome Androgen Antagonists Prostatic Neoplasms, Castration-Resistant Thiohydantoins
View on PubMed DOI
Popular Topics
Recent Journals